Novartis, Lonza strengthen biosimilars push with MS, arthritis drug deals Medical Dialogues Bureau3 Sept 2019 9:30 AM ISTNovartis's Sandoz generics unit, among the biggest biosimilars makers, on Tuesday, agreed to license from Poland's Polpharma Biologics a version of...
Novartis Rydapt wins EU approval for AML, other diseases Ruby Khatun Khatun22 Sept 2017 9:57 AM ISTZURICH: Swiss drugmaker Novartis on Wednesday won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML)...